Dr John Walshe

Senior Developer



Moleculomics offers AI-driven molecular discovery services for drug discovery, toxicity screening and precision medicine at any scale, via the Human3DProteome platform. The application of AI to genome scale molecular structure and interaction data has resulted in technologies that are globally unique in their extent and algorithmic reach, with high predictive accuracy, continually optimised by validation with the company’s in vitro knowledgebase of millions of receptor-compound interactions. The company is technologically rich, operates in key sectors, and possesses enormous opportunity in further converting capabilities to addressing the specific molecular discovery needs of industry.

« Back